摘要
目的 探讨紫杉醇静脉化疗联合腹腔热灌注顺铂治疗晚期卵巢癌肿瘤细胞减灭术后患者的疗效和不良反应。方法 将我院66例晚期卵巢癌肿瘤细胞减灭术后患者采用随机数字表法均分为2组,观察组33例给予紫杉醇静脉化疗联合腹腔热灌注顺铂,对照组33例给予紫杉醇联合顺铂静脉化疗,比较2组的肿瘤控制、腹腔积液控制、疾病无进展生存时间、KPS评分、不良反应等。结果 观察组和对照组肿瘤控制有效率分别为81.8%、42.4%,差异有统计学意义(P<0.05);腹腔积液控制有效率分别为87.9%、39.4%,差异有统计学意义(P<0.05)。观察组和对照组中位疾病无进展生存时间(95%CI)分别为30(27.1~32.2)个月、20(17.3~21.9)个月,差异有统计学意义(P<0.05)。观察组和对照组生活质量改善率分别为87.9%、51.5%,差异有统计学意义(P<0.05)。2组骨髓抑制、肝功能损伤、胃肠道反应发生率比较差异均无统计学意义(P均>0.05)。结论 晚期卵巢癌肿瘤细胞减灭术后行腹腔热灌注化疗可提高患者的肿瘤控制率、减少腹腔积液,延长疾病无进展生存时间,改善患者的生活质量,但不增加并发症和不良反应。
Objective To investigate the efficacy and adverse reactions of paclitaxel intravenous chemotherapy combined with peritoneal heat infusion with cisplatin in the treatment of advanced ovarian cancer after cytoreductive surgery. Methods Sixty-six patients with advanced ovarian cancer after cytoreductive surgery were randomly divided into two groups,33 patients of the observation group receivedpaclitaxel intravenous chemotherapy combined with peritoneal heat infusion with cisplatin, 33 patients of the control group were treated with paclitaxel plus cisplatin intravenous chemotherapy.The tumor control, peritoneal effusion control, disease progression-free survival time, KPS score, adverse reactions were compared between the two groups. Results The effective rates of tumor control in the observation group and the control group were 81.8% and 42.4%, respectively,there was statistically significant difference ( P <0.05). The effective rates of peritoneal effusion control were 87.9% and 39.4%, respectively, and the difference was statistically significant ( P <0.05). In the observation group and the control group, the median disease progression-freesurvival (95% CI ) were 30 (27.1-32.2) months and 20 (17.3-21.9) months, respectively , and the difference was statistically significant ( P <0.05). The improvement rates of quality of life in the observation group and the control group were 87.9% and 51.5%, respectively,and the difference was statistically significant ( P <0.05). There was no significant difference in the incidence of bone marrow suppression, liver function injury and gastrointestinal reaction between the two groups ( P all>0.05). Conclusion For the advanced ovarian cancer after cytoreductive surgery, paclitaxel intravenous chemotherapy combined with peritoneal heat infusion with cisplatin can improve the tumor control rate, reduce the peritoneal effusion, prolong the progression-free survival and improve the quality of life of patients without increasing complications and adverse reactions.
作者
赵虎
王志红
王武亮
方莹
王利君
陈志龙
徐臻
褚璐璐
ZHAO Hu;WANG Zhihong;WANG Wuliang;FANG Ying;WANG Lijun;CHEN Zhilong;XU Zhen;CHU Lulu(Department of Gynaecology, the Second Affiliated Hospital, Zhengzhou University, Zhengzhou 450014, China)
出处
《肿瘤基础与临床》
2019年第1期24-27,共4页
journal of basic and clinical oncology
基金
河南省医学科技攻关计划项目(201702089)
关键词
晚期卵巢癌
紫杉醇
顺铂
腹腔热灌注
advanced ovarian cancer
paclitaxel
cisplatin
peritoneal thermal perfusion
